Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

NCT01136161 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Latent Tuberculosis Infection
Tuberculosis

Interventions

BIOLOGICAL: RUTI
BIOLOGICAL: RUTI
BIOLOGICAL: RUTI
BIOLOGICAL: RUTI Matching Placebo

Sponsor

Archivel Farma S.L.

Collaborators

[object Object]